Phathom Pharmaceuticals Inc (PHAT NASDAQ) stock market data APIs
$9.5249
-0.46(-4.8%)
as of September 4, 2026
Try our APIs with
free plan!
Phathom Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Prev. Close
9.5249
Open
9.0643
High
9.5515
Low
8.9754
52 wk Range
8.21-18.31
Market Cap
769 M
Shares Outstanding
80 901 K
Revenue
240 M
EPS
-0.08
Beta
0.509
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Phathom Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phathom Pharmaceuticals Inc data using free add-ons & libraries
Get Phathom Pharmaceuticals Inc Fundamental Data
Phathom Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 240 M
- EBITDA: -40 134 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Phathom Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-07-30
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phathom Pharmaceuticals Inc News
New
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- PHAT shareholders absorbed the loss when Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) issued FY 2026 revenue guidance with a high end of $325 million -- b...
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2026 MANAGEMENT VIEW * "For the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, e...
Phathom Pharma Completes Enrollment In Phase 2 PHalcon-EoE-201 For Eosinophilic Esophagitis
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT), which develops treatments for gastrointestinal diseases, on Tuesday announced that it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical...
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Dynamics Revenue more than doubled year-over-year, driven by the strategic pivot to prioritize high-...
Get Phathom Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
